CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 39 enrolled
Drug / intervention
RPh201, botanical drug product +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01513967
NCT01513967Phase 2Completed
CompareCT.gov

A Randomized Single and Multiple Dose Study Evaluating the Safety and Tolerability of RPh201 in Healthy Subjects and in Adults With Alzheimer's Disease

Regenera Pharma Ltd·interventional·Posted Jan 20, 2012·Updated Mar 23, 2020

In Brief

A Phase 2 clinical trial evaluating RPh201, botanical drug product and Placebo for Healthy Volunteers and Moderate to Severe Alzheimer Patients. Completed, enrolled 39 participants across 2 sites.

Detailed Summary

This is a dual-centre, Phase I/IIa study, in healthy subjects and subjects with AD to investigate the safety, tolerability, cognitive, and behavioural effects of RPh201. The study will be divided into three parts: A, B, and C (NOT Performed)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteers, Moderate to Severe Alzheimer Patients
CountriesCanada
CollaboratorsSyneos Health

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJan 20, 2012
Enrollment StartJan 1, 2012
Primary CompletionJun 1, 2015
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 14.5 years ago

Interventions

RPh201, botanical drug productdrug

SC administration at varying doses

Placebodrug

SC administration at varying doses